Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells

23 Mar 2023

Abstract excerpt

All- trans -retinoic acid (ATRA)-based differentiation therapy of acute promyelocytic leukemia (APL) represents one of the most clinically effective examples of precision medicine and the first example of targeted oncoprotein degradation. The success of ATRA in APL, however, remains to be translated to non-APL acute myeloid leukemia (AML). We previously showed that aberrant histone modifications, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37035245
DOI: 10.3389/fcell.2023.1076458

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cellsPMID 37035245Read ↗

Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid LeukemiaSemantic proximity Read ↗

Targeting chromatin modifying complexes in acute myeloid leukemiaSemantic proximity Read ↗

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypesSemantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutationsSemantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.Semantic proximity Read ↗

The epigenetic role of EZH2 in acute myeloid leukemiaSemantic proximity Read ↗

Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemiaSemantic proximity Read ↗

Recent Developments in Differentiation Therapy of Acute Myeloid LeukemiaSemantic proximity Read ↗

Epigenetic-based differentiation therapy for Acute Myeloid LeukemiaSemantic proximity Read ↗

Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AMLSemantic proximity Read ↗

Recent Developments in Differentiation Therapy of Acute Myeloid LeukemiaSemantic proximity Read ↗

The biology of novel dual histone methyltransferase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.